AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03231319 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral nerve block and lateral femoral cutaneous nerve with IV-PCA
Description: 1. Femoral nerve block: The injection was performed under ultrasound guidance. Femoral nerve was identified in the femoral neurovascular bundle below or around inguinal ligament. The needle is threaded with lateral to medial approach. Local anesthetics will be deposited around the femoral nerve, the standardization of protocol is that femoral nerve should be lifted off from iliacus muscle. Anesthetic regimen: 2% xylocaine 10mL + 0.5% bupivacaine 10mL.~2. Lateral femoral cutaneous nerve block: The injection was performed under ultrasound guidance. Lateral femoral cutaneous nerve was identified in the fascia plane between sartorius muscle and tensor fascia lata muscle. Anesthetic regimen: 2% xylocaine 5mL + 0.5% bupivacaine 5mL
Study NCT03493607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMO-01
Description: Subjects will receive a single 6-hour intravenous infusion for a total dose administration or 120 mg/m2 of AMO-01.
Study NCT03513458 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: A single 1mg/kg subcutaneous injection (up to 100 mg) of Anakinra will be administered at the onset of the LPR, roughly three hours post allergen challenge, to model Anakinra use in an emergency care setting.
Study NCT03231319 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: IV-PCA
Description: IV-PCA was programmed and provided to the patient for optimize pain control
Study NCT04487743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients were randomly assigned, in a 2:1 ratio, to receive once-daily subcutaneous injections of liraglutide, starting at a dose of 0.6 mg with weekly 0.6-mg increments to 3.0 mg, or placebo; both groups received counseling on lifestyle modification
Study NCT04487743 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients were randomly assigned, in a 2:1 ratio, to receive once-daily subcutaneous injections of liraglutide, starting at a dose of 0.6 mg with weekly 0.6-mg increments to 3.0 mg, or placebo; both groups received counseling on lifestyle modification
Study NCT01904006 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: New Culture Condition
Description: Intervention group embryos cultured grouped (5 embryos per drop) under low oxygen tension (5%) in benchtop incubators.
Study NCT03513458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anakinra Matching Placebo
Description: A single dose of matching placebo will be administered at the onset of the LPR, roughly three hours post allergen challenge, to model Anakinra use in an emergency care setting.
Study NCT03513458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermatophagoides Farinae
Description: Standardized house dust mite Dermatophagoides farinae (D. farinae) allergen extract at 30,000 allergen units (AU)/mL for inhalation (provided by Greer Laboratories, Lenoir, NC).
Study NCT01904006 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Culture Condition
Description: Control group embryos cultured individually (1 embryo per drop) under atmospheric oxygen tension (20%) in large-box incubators.
Study NCT04056975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Anti-CD19m-CD3 Antibody Injection
Description: Intravenous Infusion
Study NCT02972177 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: Transbronchial radiofrequency ablation will be performed under the guidance of navigation bronchoscopy.
Study NCT02972177 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave ablation
Description: Transbronchial microwave ablation will be performed under the guidance of navigation bronchoscopy.
Study NCT03629600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactated Ringer
Description: High-volume Lactated Ringer Solution
Study NCT03629600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rectal Form Indometacin
Description: Post-ERCP rectal administration of 100 MG Indomethacin
Study NCT04032158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib
Description: Participants received evobrutinib twice daily (BID).
Study NCT02812745 — intervention group
Intervention type: DEVICE
Intervention: recording of cardiac output
Study NCT02812745 — intervention group
Intervention type: DEVICE
Intervention: other parameters
Description: BIS (bispectral index ), PI (perfusion index ), etCO2 (end-tidal carbon dioxide ), and brain NIRS (near-infrared spectroscopy)
Study NCT03313973 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: with self stretching same muscle
Description: with self stretching
Study NCT03313973 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: with self stretching of forearm muscles
Description: without self stretching
Study NCT03891888 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intramedullary Bone Graft
Description: Patients in this group will undergo standard treatment for their open tibia shaft fracture (irrigation and debridement of their open fracture and reamed intramedullary nailing), but will also have the reamings from the medullary canal preparation collected and packed into the exposed fracture cortex
Study NCT03780257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QR-421a
Description: RNA antisense oligonucleotide for intravitreal injection
Study NCT03780257 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham-procedure (dose cohort 1&2 only)
Description: Sham-procedure (no experimental drug administered)
Study NCT00685061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: Induction
Study NCT01890070 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Dietary Supplement
Description: Mediterranean Reference Diet, High Fat Diet, Low Carbohydrate or High Protein Diet without an added dietary supplement (hazelnut, chocolate, red wine, wild mixed greens, chestnuts, olive oil)
Study NCT01234441 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Control
Description: A placebo non-nutritive beverage will be administered before dialysis sessions 3 times per week.
Study NCT01234441 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein
Description: A whey protein beverage will be administered before dialysis sessions 3 times per week.
Study NCT01234441 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Protein + Exercise
Description: A whey protein beverage will be administered before dialysis sessions 3 times per week. Patients will also exercise by stationary bicycle during dialysis sessions 3 times per week.
Study NCT03658239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inversion
Description: Inversions will be done while the subject is on the inversion table. The subject will be inverted to 135, 150 and 165 degrees. There inversion will not last longer than 3 minutes at a time. The inversion will be terminated if the subject's blood pressure drops below 50 mmHg diastolic or if the subject's blood pressure increases more than 50 mmHg systolic.
Study NCT02221687 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic formula
Description: Standard milk formula enriched with a prebiotic fiber and a probiotic strain
Study NCT02221687 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control formula
Description: Standard milk formula without pre and probiotic
Study NCT05675176 — intervention group
Intervention type: DRUG
Intervention: BCG
Description: Intravesical Instillation
Study NCT03087643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive mobilization - PM
Study NCT05161767 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Brain MRI (neuroimaging)
Description: Structural and functional brain scans will be taken.
Study NCT01193595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ombrabulin (AVE8062)
Description: Pharmaceutical form:Solution for infusion~Route of administration: Intravenous
Study NCT01193595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Pharmaceutical form:Solution for infusion~Route of administration: Intravenous
Study NCT03622073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Misoprostol treatment by Midwife
Description: Medical management of incomplete abortion
Study NCT02359188 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous vagal nerve stimulation
Description: 4 hours of transcutaneous vagal nerve stimulation
Study NCT00439569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium phenylbutyrate
Description: 500 mg/kg/day, depending upon tolerability subsequent dosages may increase to 675, 900, or 1200 mg/kg/day to identify maximum tolerated dose (MTD) and then an additional 6 participants will enroll at the MTD
Study NCT02364349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bee Venom (BV)
Description: Raw Bee Venom
Study NCT03170479 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Two doses of Vitamin D supplementation in ampoules form (ED3) were procured. Ampoule contains Cholecalciferol in 200,000 IU both for oral and intra muscular use.
Study NCT03170479 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ready to Use Therapeutic Food (RUTF)
Description: RUTF is recommended by WHO for sever malnourished children in community settings as a therapeutic diet. The quantity depends upon the child body weight.
Study NCT02364349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Essential Bee Venom (e-BV)
Description: Bee venom without Hyaluronidase, Lysophospholipase, α-D-glucosidase, PLA2, Adolapin
Study NCT03170479 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready to Use Therapeutic Food (RUTF)
Description: RUTF is recommended by WHO for sever malnourished children in community settings as a therapeutic diet. The quantity depends upon the child body weight.
Study NCT03714282 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive spinal stimulation with gait training
Description: Transcutaneous Spinal Cord Neurostimulator will deliver transcutaneous electrical spinal cord stimulation while subjects perform locomotor activities.
Study NCT03714282 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional gait training
Description: May receive up to 50 min of locomotion training without transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and overground training will depend on individual tolerance and progression.
Study NCT03714282 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Healthy control group
Description: Participant in the Healthy Control Group will participate in up to 3 assessment sessions in order to obtain comparative data for Spinal Motor Evoked Potentials (MEPs), lower extremity MVC's, sidelying EMG data and overground EMG data
Study NCT01044680 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NUTRIOSE
Description: 17 grams of NUTRIOSE consumed twice daily for 12 weeks
Study NCT01044680 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 17 g maltodextrin consumed twice daily for 12 weeks
Study NCT00546039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genistein
Description: Capsule, 30 mg, oral daily for 3 to 6 weeks
Study NCT00546039 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule
Study NCT02820883 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Staphylococcus aureus vaccine (60µg/per protein)
Description: two doses of 60µg/0.6ml per dose
Study NCT02820883 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Staphylococcus aureus vaccine (30µg/per protein)
Description: two doses of 30µg/0.6ml per dose
Study NCT02820883 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Staphylococcus aureus vaccine (15µg/per protein)
Description: two doses of 15µg/0.6ml per dose
Study NCT03230474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 50 patients of this group will receive 5 mg of 0.5% hyperbaric bupivacaine with 0.2 mg morphine in 0.5 ml volume plus 0.5 ml as placebo (total volume 2 mL)
Study NCT03230474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine-Naloxone
Description: 50 patients of this group will receive 5 mg of 0.5% hyperbaric bupivacaine with 0.2 mg morphine in 0.5 ml volume plus 5ng\\ kg naloxone in 0.5 ml volume (total volume 2mL).
Study NCT01257919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelaic Acid Foam
Description: Dermal application of Azelaic Acid Foam
Study NCT01257919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azelaic Acid Gel
Description: Dermal application of Azelaic Acid Gel
Study NCT00790101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risedronate
Study NCT00790101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raloxifene
Study NCT00790101 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02231294 — intervention group
Intervention type: DRUG
Intervention: Sifrol®
Study NCT04153617 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control honey
Description: Control honey defined as orange blossom honey. Intake daily for 3 months (40 g/day)
Study NCT04153617 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control honey
Description: Control honey defined as orange blossom honey. Intake daily for 3 months (40 g/day)
Study NCT04153617 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Modified honey with soluble fiber and polyphenols
Description: Honey modified with soluble fiber and polyphenols, with same organoleptic conditions as control honey. Intake daily for 3 months (40 g/day)
Study NCT04153617 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Modified honey with soluble fiber and polyphenols
Description: Honey modified with soluble fiber and polyphenols, with same organoleptic conditions as control honey. Intake daily for 3 months (40 g/day)
Study NCT02849314 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryosurgery
Description: Percutaneous ablation under CT or ultrasound guidance
Study NCT02849314 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Description: Percutaneous ablation under CT or ultrasound guidance
Study NCT02849314 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK immunotherapy
Description: Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
Study NCT02351843 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MECTA Spectrum 5000Q
Study NCT02351843 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MECTA Spectrum 5000Q
Study NCT00685061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath-1H
Description: Induction
Study NCT01417065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Starting dose will be 0.02 mg intravenous administered once on Day 1 over 60 minutes.
Study NCT00000113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Addition Lenses
Description: Varilux comfort with +2.00 addition
Study NCT00000113 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: single vision lenses
Study NCT01077388 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietician electronic support
Description: Dietitian-delivered behavioral intervention, that uses a patient shared EMR and e-communications, will be integrated into routine healthcare and will result in improved control of modifiable CVD risk.
Study NCT02090192 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WBV training
Study NCT02090192 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRT training
Study NCT02090192 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRT training
Study NCT00685061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclizumab
Description: Induction
Study NCT03634956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group B. Sugammadex sodium-IONM
Description: Group B.the vagal nerve is detected and then 2 mg / kg of sugammadex sodium is administered to remove the muscle relaxant effect
Study NCT05215002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone Call
Description: Patient will be called in the evening of the day of the surgery or one day after surgery and asked about any complaints
Study NCT05215002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No telephone call
Description: Patient will not be called in the evening of the day of the surgery or one day after surgery and asked about any complaints
Study NCT04762407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1910
Description: Take it once per period.
Study NCT04762407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1909
Description: Take it once per period.
Study NCT04762407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1903
Description: Take it once per period.
Study NCT04117178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Adjustment of treatment with donepezil according to serum level.
Study NCT04117178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Adjustment of treatment with memantine according to serum level.
Study NCT04117178 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Measurement of serum level of anti-dementia drug
Description: Participants allocated to the intervention arm are requested to inform the sponsor of any side effects up to 2 months after prescription of the anti-dementia drug. If so, they will have their treatment adjusted according to the serum level. Participants in the intervention group not experiencing side effects will have their treatment adjusted after 6 months based upon serum levels of the drug in question.~Participants allocated to the standard of care arm follow the usual routines of the dementia clinic but are requested to have the serum level of the prescribed drug and CYP2D6-genotype measured after 12 month.
Study NCT04117178 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Measurement of serum level of anti-dementia drug
Description: Participants allocated to the intervention arm are requested to inform the sponsor of any side effects up to 2 months after prescription of the anti-dementia drug. If so, they will have their treatment adjusted according to the serum level. Participants in the intervention group not experiencing side effects will have their treatment adjusted after 6 months based upon serum levels of the drug in question.~Participants allocated to the standard of care arm follow the usual routines of the dementia clinic but are requested to have the serum level of the prescribed drug and CYP2D6-genotype measured after 12 month.
Study NCT03975374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin/dexamethasone opthalmic solution
Description: To compare efficacy and safety in randomized patients recieving Tobradex versus Tobramycin/Dexamethasone opthamic Solution
Study NCT03975374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobradex Opthalmic Solution
Description: Tobradex Opthalmic Solution
Study NCT03935165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: 0.25 mg /(kg BW) Indocyanine Green PULSION®/ VERDYE Diagnostic Green®~- Indocyanine Green is administered Intravenously
Study NCT03497234 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Perilynx Analyzer to measure AF and VF fluid
Description: Hologic developed a rapid in-vitro diagnostic system composed of an analyzer and cassettes to identify women with intra-amniotic infection.
Study NCT00082758 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hu14.18-Interleukin-2 fusion protein
Description: Given IV
Study NCT03179007 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CTLA-4/PD-1 expressing MUC1-CAR-T
Description: Every cycle, peripheral blood mononuclear cells (PBMC) are collected on day 0, CAR-T cells are cultured in a GMP standard workshop. Patients are given a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes before cells infusion. Then the patients will receive an i.v.gtt infusion of CTLA-4 and PD-1 antibodies expressing MUC1 targeted CAR-T cells at (2-5) ×10\^7 cells/kg from day 18 to day 19 (±2 days). 2 cycles are regarded as a treatment period.
Study NCT03596658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR9549
Description: If initial dosing of SHR9549 is tolerated then subsequent cohorts will test increasing doses until a maximum tolerated dose(MTD) is defined